

Cancer Lifeline

Company Limited by Guarantee

Statement of Financial Activities (including income and expenditure account)

Year ended 31 March 2024

		2024	2023		
	Note	Unrestricted funds £	Restricted funds £	Total funds £	Total funds £
Income and endowments					
Donations and legacies	5	68,315	–	68,315	59,508
Charitable activities	6	–	386,195	386,195	344,015
Other trading activities	7	70,091	–	70,091	58,631
Other income	8	5,803	–	5,803	–
Total income		<u>144,209</u>	<u>386,195</u>	<u>530,404</u>	<u>462,154</u>
Expenditure					
Expenditure on raising funds:					
Costs of other trading activities	9	114,691	–	114,691	47,016
Expenditure on charitable activities	10,11	<u>52,079</u>	<u>405,974</u>	<u>458,053</u>	<u>422,465</u>
Total expenditure		<u>166,770</u>	<u>405,974</u>	<u>572,744</u>	<u>469,481</u>
Net expenditure		<u>(22,561)</u>	<u>(19,779)</u>	<u>(42,340)</u>	<u>(7,327)</u>
Transfers between funds		162,785	(162,785)	–	–
Net movement in funds		<u>140,224</u>	<u>(182,564)</u>	<u>(42,340)</u>	<u>(7,327)</u>
Reconciliation of funds					
Total funds brought forward		<u>370,286</u>	<u>190,544</u>	<u>560,830</u>	<u>568,157</u>
Total funds carried forward		<u>510,510</u>	<u>7,980</u>	<u>518,490</u>	<u>560,830</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 26 to 37 form part of these financial statements.

Cancer Lifeline


Company Limited by Guarantee

Statement of Financial Position

31 March 2024

	Note	2024 £	2023 £
Fixed assets			
Tangible fixed assets	17	202,550	214,581
Current assets			
Debtors	18	5,443	900
Cash at bank and in hand		372,207	363,585
		<u>377,650</u>	<u>364,485</u>
Creditors: amounts falling due within one year	20	<u>61,710</u>	<u>18,236</u>
Net current assets		<u>315,940</u>	<u>346,249</u>
Total assets less current liabilities		<u>518,490</u>	<u>560,830</u>
Net assets		<u>518,490</u>	<u>560,830</u>
Funds of the charity			
Restricted funds		7,980	190,544
Unrestricted funds		<u>510,510</u>	<u>370,286</u>
Total charity funds	23	<u>518,490</u>	<u>560,830</u>

These financial statements were approved by the board of trustees and authorised for issue on 25 November 2024, and are signed on behalf of the board by:



G Mathews
Trustee



B Montgomery
Trustee

The notes on pages 26 to 37 form part of these financial statements.

Cancer Lifeline

Company Limited by Guarantee

Statement of Cash Flows

Year ended 31 March 2024

	Note	2024 £	2023 £
Cash flows from operating activities			
Net expenditure		(42,340)	(7,327)
<i>Adjustments for:</i>			
Depreciation of tangible fixed assets		12,031	14,087
Interest payable and similar charges		1,848	2,008
Accrued expenses		8,520	—
<i>Changes in:</i>			
Trade and other debtors		(4,543)	(900)
Trade and other creditors		22,620	5,041
Cash generated from operations		(1,864)	12,909
Interest paid		(1,848)	(2,008)
Net cash (used in)/from operating activities		(3,712)	10,901
Cash flows from investing activities			
Purchase of tangible assets		—	(5,999)
Net cash used in investing activities		—	(5,999)
Net (decrease)/increase in cash and cash equivalents		(3,712)	4,902
Cash and cash equivalents at beginning of year		350,390	345,488
Cash and cash equivalents at end of year	19	<u>346,678</u>	<u>350,390</u>

The notes on pages 26 to 37 form part of these financial statements.

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements

Year ended 31 March 2024

1. General information

The charity is a public benefit entity and a private company limited by guarantee, registered in Northern Ireland. The address of the registered office is 44 Alliance Avenue, Belfast, BT14 7PJ.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Companies Act 2006.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

There are no material uncertainties about the charity's ability to continue.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees to further any of the charity's purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted funds are subjected to restrictions on their expenditure declared by the donor or through the terms of an appeal, and fall into one of two sub-classes: restricted income funds or endowment funds.

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

3. Accounting policies *(continued)*

Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:

- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably.
- legacy income is recognised when receipt is probable and entitlement is established.
- income from donated goods is measured at the fair value of the goods unless this is impractical to measure reliably, in which case the value is derived from the cost to the donor or the estimated resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers.
- income from contracts for the supply of services is recognised with the delivery of the contracted service. This is classified as unrestricted funds unless there is a contractual requirement for it to be spent on a particular purpose and returned if unspent, in which case it may be regarded as restricted.

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:

- expenditure on raising funds includes the costs of all fundraising activities, events, non-charitable trading activities, and the sale of donated goods.
- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities.
- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

3. Accounting policies *(continued)*

Tangible assets *(continued)*

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other recognised gains and losses, unless it reverses a charge for impairment that has previously been recognised as expenditure within the statement of financial activities. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other recognised gains and losses, except to which it offsets any previous revaluation gain, in which case the loss is shown within other recognised gains and losses on the statement of financial activities.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Long leasehold property	-	2% straight line
Motor vehicles	-	25% reducing balance
Equipment	-	20% reducing balance

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the charity are assigned to those units.

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

3. Accounting policies *(continued)*

Financial instruments

A financial asset or a financial liability is recognised only when the charity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs.

Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted.

Debt instruments are subsequently measured at amortised cost.

Where investments in shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in income and expenditure. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in the statement of financial activities, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised under the appropriate heading in the statement of financial activities in which the initial gain was recognised.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the repayment will lead to a reduction in future payments or a cash refund.

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

3. Accounting policies *(continued)*

Defined contribution plans *(continued)*

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as an expense in the period in which it arises.

4. Limited by guarantee

The charity is a public benefit entity and a private company limited by guarantee, registered in Northern Ireland and a registered charity in Northern Ireland. The address of the registered office is 187-189 Duncairn Gardens, Belfast, Antrim, BT15 2GF.

5. Donations and legacies

	Unrestricted Funds £	Total Funds 2024 £	Unrestricted Funds £	Total Funds 2023 £
Donations				
Donations	63,948	63,948	54,962	54,962
Collection boxes	4,367	4,367	4,546	4,546
	<u>68,315</u>	<u>68,315</u>	<u>59,508</u>	<u>59,508</u>

6. Charitable activities

	Restricted Funds £	Total Funds 2024 £	Restricted Funds £	Total Funds 2023 £
DFC (Neighbourhood Renewal)	77,948	77,948	83,319	83,319
The National Lottery Community Fund (People in Communities Programme)	50,254	50,254	60,915	60,915
HSC (Public Health Agency)	93,520	93,520	74,099	74,099
BHSCT (Carer's Support Services)	11,124	11,124	10,488	10,488
BHSCT (Primary Care Talking Therapies)	3,266	3,266	4,556	4,556
Belfast City Council (Revenue Grant)	49,981	49,981	18,500	18,500
CFNI - The Comic Relief Empower Change Core Programme	—	—	12,320	12,320
CFNI (through the Department of Health Cancer Charity Support Fund)	73,565	73,565	66,667	66,667
The National Lottery Community Fund (through Dormant Accounts NI)	26,537	26,537	13,151	13,151
	<u>386,195</u>	<u>386,195</u>	<u>344,015</u>	<u>344,015</u>

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

7. Other trading activities

	Unrestricted Funds £	Total Funds 2024 £	Unrestricted Funds £	Total Funds 2023 £
Shop income	<u>70,091</u>	<u>70,091</u>	<u>58,631</u>	<u>58,631</u>

8. Other income

	Unrestricted Funds £	Total Funds 2024 £	Unrestricted Funds £	Total Funds 2023 £
Sundry income	<u>5,803</u>	<u>5,803</u>	<u>–</u>	<u>–</u>

9. Costs of other trading activities

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £
Costs of other trading activities - Shop costs	<u>114,691</u>	<u>–</u>	<u>114,691</u>

	Unrestricted Funds £	Restricted Funds £	Total Funds 2023 £
Costs of other trading activities - Shop costs	<u>–</u>	<u>47,016</u>	<u>47,016</u>

10. Expenditure on charitable activities by fund type

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £
Charitable activity	36,448	354,030	390,478
Support costs	<u>15,631</u>	<u>51,944</u>	<u>67,575</u>
	<u>52,079</u>	<u>405,974</u>	<u>458,053</u>

	Unrestricted Funds £	Restricted Funds £	Total Funds 2023 £
Charitable activity	117,029	48,608	165,637
Support costs	<u>–</u>	<u>256,828</u>	<u>256,828</u>
	<u>117,029</u>	<u>305,436</u>	<u>422,465</u>

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

11. Expenditure on charitable activities by activity type

	Activities undertaken directly	Support costs	Total funds 2024	Total fund 2023
	£	£	£	£
Charitable activity	390,478	54,235	444,713	418,865
Governance costs	—	13,340	13,340	3,600
	<u>390,478</u>	<u>67,575</u>	<u>458,053</u>	<u>422,465</u>

12. Analysis of support costs

	Analysis of support costs	Total 2024	Total 2023
	£	£	£
Staff costs	—	—	206,334
Premises	11,059	11,059	13,921
Communications and IT	5,307	5,307	2,321
General office	36,021	36,021	28,644
Finance costs	1,848	1,848	2,008
Governance costs	13,340	13,340	3,600
	<u>67,575</u>	<u>67,575</u>	<u>256,828</u>

13. Net expenditure

Net expenditure is stated after charging/(crediting):

	2024	2023
	£	£
Depreciation of tangible fixed assets	<u>12,031</u>	<u>14,087</u>

14. Auditors remuneration

	2024	2023
	£	£
Fees payable for the audit of the financial statements	<u>4,260</u>	<u>—</u>

15. Staff costs

The total staff costs and employee benefits for the reporting period are analysed as follows:

	2024	2023
	£	£
Wages and salaries	235,757	208,355
Social security costs	18,814	12,647
Employer contributions to pension plans	20,424	19,125
	<u>274,995</u>	<u>240,127</u>

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

15. Staff costs *(continued)*

The average head count of employees during the year was 12 (2023: 13).

No employee received employee benefits of more than £60,000 during the year (2023: Nil).

Key Management Personnel

Key management personnel include all persons that have authority and responsibility for planning, directing and controlling the activities of the charity. The total compensation paid to key management personnel for services provided to the charity was £106,267.

16. Trustee remuneration and expenses

No Trustee received emoluments during the year (2023:Nil)

The Trustees' received in total £2,172 (2023:£706) in reimbursement of expenses. The reimbursement is made for cost of travelling on Charity business in relation to their duties as Trustees' and also (as with other volunteers) the reimbursement of costs incurred during support visitations.

17. Tangible fixed assets

	Long leasehold property £	Motor vehicles £	Equipment £	Total £
Cost				
At 1 April 2023 and 31 March 2024	<u>293,983</u>	<u>11,000</u>	<u>129,380</u>	<u>434,363</u>
Depreciation				
At 1 April 2023	103,997	6,875	108,910	219,782
Charge for the year	5,880	1,031	5,120	12,031
At 31 March 2024	<u>109,877</u>	<u>7,906</u>	<u>114,030</u>	<u>231,813</u>
Carrying amount				
At 31 March 2024	<u>184,106</u>	<u>3,094</u>	<u>15,350</u>	<u>202,550</u>
At 31 March 2023	<u>189,986</u>	<u>4,125</u>	<u>20,470</u>	<u>214,581</u>

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

18. Debtors

	2024	2023
	£	£
Trade debtors	900	–
Prepayments and accrued income	3,324	–
Other debtors	1,219	900
	<u>5,443</u>	<u>900</u>

19. Cash and cash equivalents

Cash and cash equivalents comprise the following:

	2024	2023
	£	£
Cash at bank and in hand	372,207	363,585
Bank overdrafts	(25,529)	(13,195)
	<u>346,678</u>	<u>350,390</u>

20. Creditors: amounts falling due within one year

	2024	2023
	£	£
Bank loans and overdrafts	25,529	13,195
Trade creditors	2,778	5,041
Accruals and deferred income	33,032	–
Social security and other taxes	371	–
	<u>61,710</u>	<u>18,236</u>

21. Deferred income

	2024	2023
	£	£
Amount deferred in year	<u>24,512</u>	<u>–</u>

22. Pensions and other post retirement benefits

Defined contribution plans

The amount recognised in income or expenditure as an expense in relation to defined contribution plans was £20,424 (2023: £19,125).

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

23. Analysis of charitable funds

Unrestricted funds

	At 1 April 2023 £	Income £	Expenditure £	Transfers £	At 31 March 2024 £
General Funds	146,422	144,209	(166,770)	(61,719)	62,142
General funds - property fund	–	–	–	161,996	161,996
Designated Fund	223,864	–	–	62,508	286,372
	<u>370,286</u>	<u>144,209</u>	<u>(166,770)</u>	<u>162,785</u>	<u>510,510</u>

	At 1 April 2022 £	Income £	Expenditure £	Transfers £	At 31 March 2023 £
General Funds	145,312	118,139	(117,029)	–	146,422
General funds - property fund	–	–	–	–	–
Designated Fund	223,864	–	–	–	223,864
	<u>369,176</u>	<u>118,139</u>	<u>(117,029)</u>	<u>–</u>	<u>370,286</u>

Restricted funds

	At 1 April 2023 £	Income £	Expenditure £	Transfers £	At 31 March 2024 £
Restricted Funds - operating fund	5,108	–	–	(5,108)	–
Restricted - Property Fund	161,996	–	–	(161,996)	–
DFC (Neighbourhood Renewal)	8,830	77,948	(86,778)	–	–
National Lottery Community Fund (People in Communities)	14,610	50,254	(64,864)	–	–
HSC (Public Health Agency)	–	93,520	(93,520)	–	–
BHSCT (Carer's support service)	–	11,124	(11,124)	–	–

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

23. Analysis of charitable funds *(continued)*

BHSCT (Primary care talking therapies)	–	3,266	(3,266)	–	–
Belfast City Council (Revenue Grant)	–	49,981	(49,981)	–	–
CFNI (through DOH Carer's grant)	–	6,898	(6,898)	–	–
CFNI (through DOH Cancer Charity Support Fund)	–	66,667	(58,687)	–	7,980
National Lottery Community Fund (Dormant Accounts)	–	26,537	(30,856)	4,319	–
	<u>190,544</u>	<u>386,195</u>	<u>(405,974)</u>	<u>(162,785)</u>	<u>7,980</u>

	At 1 April 2022 £	Income £	Expenditure £	Transfers £	At 31 March 2023 £
Restricted Funds - operating fund	36,985	344,015	(352,452)	–	28,548
Restricted - Property Fund	161,996	–	–	–	161,996
DFC (Neighbourhood Renewal)	–	–	–	–	–
National Lottery Community Fund (People in Communities)	–	–	–	–	–
HSC (Public Health Agency)	–	–	–	–	–
BHSCT (Carer's support service)	–	–	–	–	–
BHSCT (Primary care talking therapies)	–	–	–	–	–
Belfast City Council (Revenue Grant)	–	–	–	–	–
CFNI (through DOH Carer's grant)	–	–	–	–	–
CFNI (through DOH Cancer Charity Support Fund)	–	–	–	–	–
National Lottery Community Fund (Dormant Accounts)	–	–	–	–	–
	<u>198,981</u>	<u>344,015</u>	<u>(352,452)</u>	<u>–</u>	<u>190,544</u>

Cancer Lifeline

Company Limited by Guarantee

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

23. Analysis of charitable funds *(continued)*

Transfers have taken place in the year in relation to the Property Fund as this fund is no longer restricted as the grant restriction has ended.

Transfers have also taken place in the year to reclassify funds to unrestricted funds as the funds are available for any use, no restrictions have been placed on this.

24. Analysis of net assets between funds

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £
Tangible fixed assets	202,550	–	202,550
Current assets	345,158	32,492	377,650
Creditors less than 1 year	(37,198)	(24,512)	(61,710)
Net assets	<u>510,510</u>	<u>7,980</u>	<u>518,490</u>

	Unrestricted Funds £	Restricted Funds £	Total Funds 2023 £
Tangible fixed assets	58,465	156,116	214,581
Current assets	330,057	34,428	364,485
Creditors less than 1 year	(18,236)	–	(18,236)
Net assets	<u>370,286</u>	<u>190,544</u>	<u>560,830</u>

25. Analysis of changes in net debt

	At 1 Apr 2023 £	Cash flows £	At 31 Mar 2024 £
Cash at bank and in hand	363,585	8,622	372,207
Bank overdrafts	(13,195)	(12,334)	(25,529)
	<u>350,390</u>	<u>(3,712)</u>	<u>346,678</u>

26. Contingencies

A contingent liability exists to repay grants and Trust monies received should certain conditions not be fulfilled by the charity. In the opinion of the Trustees, the terms of the Letters of Offers have been, or will be, complied with and no liability is expected.

27. Ethical standards

In common with many other businesses of our size and nature we use our auditors to prepare and submit returns to the tax authorities and assist with the preparation of the financial statements.